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Purpose: To assess the safety and effectiveness of a novel, minimally invasive interspinous 
spacer in patients with moderate lumbar spinal stenosis (LSS).
Methods: A total of 53 patients (mean age, 70 ± 11 years; 45% female) with intermittent 
neurogenic claudication secondary to moderate LSS, confirmed on imaging studies, were treated 
with the Superion® Interspinous Spacer (VertiFlex, Inc, San Clemente, CA) and returned for 
follow-up visits at 6 weeks, 1 year, and 2 years. Study endpoints included axial and extremity 
pain severity with an 11-point numeric scale, Zurich Claudication Questionnaire (ZCQ), back 
function with the Oswestry Disability Index (ODI), health-related quality of life with the 
Physical Component Summary (PCS) and Mental Component Summary (MCS) scores from 
the SF-12, and adverse events.
Results: Axial and extremity pain each decreased 54% (both P , 0.001) over the 2-year 
follow-up period. ZCQ symptom severity scores improved 43% (P , 0.001) and ZCQ physical 
function improved 44% (P , 0.001) from pre-treatment to 2 years post-treatment. A statistically 
significant 50% improvement (P , 0.001) also was noted in back function. PCS and MCS each 
improved 40% (both P , 0.001) from pre-treatment to 2 years. Clinical success rates at 2 years 
were 83%–89% for ZCQ subscores, 75% for ODI, 78% for PCS, and 80% for MCS. No device 
infection, implant breakage, migration, or pull-out was observed, although two (3.8%) patients 
underwent explant with subsequent laminectomy.
Conclusion: Moderate LSS can be effectively treated with a minimally invasive interspinous 
spacer. This device is appropriate for select patients who have failed nonoperative treatment 
measures for LSS and meet strict anatomical criteria.
Keywords: Superion, axial pain, extremity pain
Introduction
Lumbar spinal stenosis (LSS) is a progressive degenerative narrowing of the central 
  spinal canal and/or lateral neuroforamen that commonly leads to neurogenic claudication 
by compression of the spinal nerves and associated vasculature.1 LSS currently affects 
1 million people in the United States and is the most common indication for spinal 
surgery in the elderly.2 While some patients with LSS are asymptomatic, most present 
with leg pain, numbness, and tingling that is exacerbated with ambulation and extension 
movements of the spinal column. Ultimately, these symptoms result in lower quality 
of life and impaired functional capacity.3
Despite the lack of convincing evidence to support their use, initial management 
of mild radicular symptoms focuses on nonsurgical options and includes activity 
modification, physical therapy, analgesic and anti-inflammatory medications, and 
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epidural spinal injections.4 However, none of these therapies 
has demonstrated long-term effectiveness since they do not 
alter the course of disease progression.5,6 As the disease 
worsens to yield moderate symptoms, patients must tolerate 
progressively persistent pain and functional impairment since 
no additional treatment options are available. Ultimately, 
as the disease advances to produce chronic and severe 
symptoms, open spinal surgery such as decompressive 
laminectomy with or without fusion is often required to 
alleviate symptoms.7,8
Minimally invasive lumbar procedures represent a 
viable alternative that addresses the therapeutic gap for 
patients with moderate radicular symptoms. In particular, 
interspinous process decompression utilizes a spacer that 
is implanted between contiguous spinous processes to limit 
back extension at the symptomatic level, thereby improving 
patient symptoms.9 Potential advantages of this procedure 
versus other surgical procedures include lower neural 
injury risk, ability to intervene earlier in the disease process 
before symptoms become debilitating, and preservation 
of anatomical structures which allows the option of more 
invasive surgery in the future, should severe symptoms 
recur or further mechanical changes ensue. The X-STOP® 
Interspinous Process Decompression System (Medtronic, 
Inc, Minneapolis, MN) has been extensively studied in 
clinical trials,10–16 although reports with other spacers are 
less common.17–21 Despite overall favorable results with 
these devices in anatomically suitable patients, the clinical 
benefit of interspinous spacers is debatable given the 
paucity of available long-term data and the risk for device-
related complications.22,23 This study was conducted to 
evaluate 2-year clinical outcomes in patients with moderate 
LSS who were treated with a novel, minimally invasive 
interspinous spacer.
Materials and methods
Patients
This single-arm prospective study enrolled 53 patients 
with moderate LSS between July 2007 and March 2008. 
All patients were treated with the Superion® Interspinous 
Spacer (VertiFlex, San Clemente, CA). Inclusion criteria for 
this study included: (1) diagnosis of moderate LSS, defined 
as 25%–50% reduction in lateral/central foramen diameter 
compared with adjacent levels and radiographic evidence 
(magnetic resonance imaging or computed tomography) 
of thecal sac and/or cauda equine compression, nerve root 
impingement by either osseous or nonosseous elements, 
and/or hypertrophic facets with canal encroachment; 
(2) persistent leg, buttock, or groin pain, with or without 
back pain, that was relieved by lumbar flexion; and 
(3) unsuccessful nonoperative treatment for at least 3 months. 
Exclusion criteria included (1) axial back pain only, (2) grade 
II–V spondylolisthesis, (3) unremitting back pain in any 
spinal position, (4) active systemic disease that may affect the 
welfare of the patient, (5) vertebral osteoporosis or history of 
vertebral fracture, and (6) pregnant or lactating female. The 
procedures used in this clinical study were in accordance with 
the recommendations of the Helsinki Declaration, and each 
patient provided written informed consent before surgery.
Intervention
The Superion device is a single-piece, self-expanding 
titanium implant that is delivered via percutaneous access and 
deployed between the spinous processes of the symptomatic 
vertebral levels (Figure 1A and B). The minimally invasive 
procedure began with the patient lying prone on a radiolucent 
table with the lumbar spine in a neutral or slightly flexed 
position. Using fluoroscopic guidance or direct visualization, 
the symptomatic level was identified and a 12–15 mm 
midline incision was made. The supraspinous ligament was 
longitudinally dissected at the symptomatic level and was 
then dilated to ensure adequate room to maneuver within the 
interspinous space. A cannula was inserted over the dilator, 
and proper alignment and depth were ensured before dilator 
removal. Next, an interspinous gauge was inserted through 
the cannula to determine proper implant size selection. Final 
midline positioning was confirmed under fluoroscopy.
The appropriately sized spacer was delivered through 
the cannula using a device inserter that loaded the implant, 
inserted it into the interspinous space via the cannula, 
and then deployed the implant. Proper device placement 
was confirmed with fluoroscopy. Finally, the inserter and 
cannula were removed, and the incision was sutured in a 
standard fashion.
Figure  1  (A)  Postero-anterior  and  (B)  lateral  radiographic  images  showing  a 
properly placed Superion® Interspinous Spacer (VertiFlex, Inc, San Clemente, CA).
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Outcomes
Patients were assessed pre-treatment and then returned for 
follow-up visits at 6 weeks and at 1 and 2 years post-  treatment. 
Axial and extremity pain severity was measured with an 
11-point (0–10) numeric pain scale at pre-  treatment and 
postoperatively only. The Zurich Claudication Questionnaire 
(ZCQ) was utilized to assess patient-reported measures of 
symptom severity, physical function, and patient   satisfaction.14 
Back-specific functional disability was   measured with the 
Oswestry Disability Index (ODI)   (version 2) on a 0%–100% 
scale.24 Health-related quality of life was assessed with the 
SF-12®, version 2, (Medical   Outcomes Trust, Hanover, 
NH) and Physical Component Summary (PCS) and Mental 
  Component Summary (MCS) scores were recorded.25 Safety 
was assessed by incidence of reported adverse events through 
the 2-year follow-up period.
Data analysis
Data were analyzed using Predictive Analytics Software, 
version 18 (SPSS, Inc, Chicago, IL). Patients included in this 
report had 2-year data available for at least one of the follow-
ing variables: axial pain, extremity pain, ZCQ, ODI, PCS, 
and MCS. Continuous data were reported as mean ± standard 
deviation, and categorical data were reported as frequencies 
and percentages. Longitudinal changes in patient outcomes 
were analyzed with repeated measures analysis of variance. 
Clinical success at each follow-up period was defined as 
a $30% improvement in pain scores,26,27 $0.5 point improve-
ment in ZCQ symptom severity and physical function,14 ZCQ 
patient satisfaction score #2.5,14 $30% improvement in 
ODI,26,28 $5.7-point improvement in PCS,29 and $6.3-point 
improvement in MCS.29
Results
Patient characteristics included mean age of 70 ± 11 years, 
45% female, 98% (52 of 53) with single level disease, mod-
erate disability, and severe back pain with a mean duration 
of 30 ± 31 months. Implant size ranged from 8 to 16 mm 
with the 11–13 mm devices accounting for two-thirds of 
implants (Table 1).
Axial and extremity pain severity
Axial pain decreased 54% (P , 0.001) from 8.9 ± 1.4 at pre-
treatment to 4.1 ± 3.4 postoperatively (Figure 2A). At the 
postoperative follow-up, 73% (29 of 40) of patients achieved the 
clinical success threshold of a $30% improvement   (Figure 2B). 
Similar improvements in extremity pain were   realized with a 
mean improvement of 54% from 8.7 ± 1.9 at pre-treatment and 
4.1 ± 3.2 postoperatively (P , 0.001). Extremity pain clinical 
success was 74% (28 of 38) postoperatively.
ZCQ
ZCQ symptom severity scores improved 43% (P , 0.001), 
and ZCQ physical function improved 44% (P , 0.001) from 
Table 1 Patient characteristics
Characteristic N Value
Age, mean ± SD, years 53 70 ± 11
Female, n (%) 53 24 (45)
Previous spine operation, n (%) 52 4 (8)
Current smoker, n (%) 53 4 (8)
Duration of symptoms, mean ± SD, months 47 30 ± 31
Axial pain score, mean ± SD 45 8.8 ± 1.9
Extremity pain score, mean ± SD 41 8.8 ± 1.9
ZCQ symptom severity, mean ± SD 52 3.4 ± 0.6
ZCQ physical function, mean ± SD 53 3.2 ± 0.4
Oswestry Disability Index, mean ± SD, % 52 57 ± 14
Physical Component Summary score, mean ± SD 53 31 ± 7
Mental Component Summary score, mean ± SD 53 33 ± 8
Abbreviations: SD, standard deviation; ZCQ, Zurich Claudication Questionnaire.
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Figure  2  (A)  Improvement  in  postoperative  axial  and  extremity  pain  scores 
(mean ± 95% confidence interval). (B) Clinical success rates ($30% improvement).
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pre-treatment to 2 years post-treatment (Figure 3A). The 
mean ZCQ patient satisfaction score was 1.9 at all follow-up 
visits. When using the standard criteria of an improvement 
of 0.5 points or greater to define 2-year clinical success, 
83% (43 of 52) of patients achieved ZCQ symptom severity 
clinical success, and 89% (47 of 53) of patients achieved 
ZCQ physical function clinical success. Patient   satisfaction 
clinical success (score #2.5) at 2 years was 87% (46 of 53). 
The proportion of patients that achieved at least two of 
three clinical success criteria at 2 years was 87% (45 of 52) 
(Figure 3B).
Back-specific functional impairment
A statistically significant 50% improvement (P , 0.001) in back 
function was noted through 2 years post-treatment   (Figure 4A). 
When using the standard criteria of an improvement of 30% 
or greater to define clinical success, 75% (39 of 52) of patients 
achieved ODI clinical success at 2 years (Figure 4B).
Quality of life assessment
PCS and MCS each improved 40% (P , 0.001) from 
  pre-treatment to 2 years (Figure 5A). Through 2 years, MCS 
clinical success was achieved in 80% (40 of 50) of patients, 
0
1
2
3
4
5
0
1
2
3
4
5
P
h
y
s
i
c
a
l
 
f
u
n
c
t
i
o
n
S
y
m
p
t
o
m
 
s
e
v
e
r
i
t
y
Baseline
pre-treatment
6
weeks
1
year
2
years
Symptom
severity
43%
P < 0.001
44%
P < 0.001
Overall
Improvement
Physical
function
0
20
40
60
80
100
6 weeks 1 year 2 years
C
l
i
n
i
c
a
l
 
s
u
c
c
e
s
s
 
r
a
t
e
s
 
(
%
)
⁄
⁄
⁄
⁄
⁄
⁄
⁄
⁄
⁄
⁄
⁄
⁄
Symptom
severity
Physical
function
Patient
satisfaction
At least 2 of 3 
domains
B
A
Figure 3 (A) Improvement in Zurich Claudication Questionnaire scores through 2 years post-treatment (mean ± 95% confidence interval). (B) Clinical success rates ($0.5 
points symptom severity and physical function improvement, #2.5 points patient satisfaction) through 2 years post-treatment.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
230
Shabat et alClinical Interventions in Aging 2011:6
while PCS clinical success was achieved in 78% (39 of 50) 
of patients (Figure 5B).
Adverse events
No device infection, implant breakage, migration, or pull-out 
was observed through the 2-year follow-up visit. Two (3.8%) 
patients underwent explant with subsequent laminectomy due 
to persistent radicular symptoms.
Discussion
The Superion Interspinous Spacer is a novel, minimally 
invasive device that offers excellent safety and effectiveness 
for the patient with intermittent neurogenic claudication 
secondary to moderate LSS based on the 2-year outcomes 
reported in the current study. All clinical markers of pain, 
function, and health-related quality of life improved by 
approximately 50% over the 2-year follow-up period.
The outcomes observed in this study compare favorably 
to those reported with the X-STOP spacer with improvements 
of 44% for ZCQ physical function, 45% for ZCQ symptom 
severity, 36% for extremity pain, and 38% for ODI in these 
studies.12,16 Furthermore, the 3.8% reintervention rate in the 
current series approximates the 1.0%–4.6% reintervention 
rate reported in the largest X-STOP trials.12,16
The safety and effectiveness of the Superion device also 
appears to be similar to that of laminectomy.   Success rates 
of 74%–89% were observed, depending on the   outcome, in 
the current series. Overall success rates with laminectomy 
range from 26% to 100%.8,30–32 No   device-complications 
were observed in the current series, although   persistent 
radicular symptoms requiring device explant were reported 
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Figure  4  (A)  Improvement  in  ODI  scores  through  2  years  post-treatment 
(mean ± 95% confidence interval). (B) Clinical success rates ($30% improvement) 
through 2 years post-treatment. 
Abbreviation: ODI, Oswestry Disability Index.
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in two (3.8%) patients. Common complications of 
laminectomy are dural tear (6%), infection (3%), and deep 
vein thrombosis (3%).8
Despite the low incidence of complications in this 
series, several concerns have been raised regarding use 
of interspinous spacers including device subsidence, 
spinous process fracture, treated segment destabilization, 
and adjacent segment degeneration. Although concern for 
device subsidence has been acknowledged with interspinous 
spacers, no known study has reported this complication to 
date. Spinous process fracture has been noted in 0%–6% of 
patients treated with interspinous spacers who were followed 
with plain radiographs,16,33,34 although one study reported 
a 29% fracture incidence with computed tomographic 
imaging.35 Low lumbar bone mineral density has been 
suggested as a potential risk factor for device fracture, and 
severe osteoporosis is a common exclusion criterion for 
these devices.35 Destabilization of the treated segment is 
purported as a potential risk of interspinous spacer treatment. 
Biomechanical studies have yielded mixed conclusions on 
the effect of an implanted interspinous spacer on segmental 
range of motion,36,37 and no definitive evidence from human 
trials currently exists. Despite concern for adjacent segment 
degeneration with long-term interspinous spacer implant, 
no biomechanical or human study has demonstrated that 
an interspinous spacer has deleterious effects on adjacent 
levels.36,38,39 Overall, complications with interspinous spacers 
are uncommon and seem to be primarily attributable to 
improper patient selection.34
The appropriateness of patients with low-grade slip for 
interspinous spacer treatment is debatable. The study of 
Verhoof and colleagues40 investigated interspinous spacer 
use in 12 patients (9 with grade I slip and 2 with grade II slip) 
and reported a 58% reintervention rate within 2 years. In the 
largest study in interspinous spacer use in patients with low-
grade slip, patients treated with interspinous spacer (n = 42) 
had a similar reintervention rate (12%) as subjects treated 
nonoperatively (n = 33).33 Implantation of an interspinous 
spacer prevents motion at the implanted level41 and results in 
no progression of spondylolisthesis over time.33 Most studies 
of interspinous spacers allow enrolment of patients with 
grade I slip, and no compelling evidence exists to exclude 
these patients from treatment consideration.23,34
Patient selection is critical to ensure a high probability 
of treatment success with an interspinous spacer. Patients 
must have confirmatory imaging evidence of LSS, relief of 
symptoms during lumbar flexion, adequate vertebral bone 
mineral density, and must be nonresponsive to conservative 
care efforts in order to realize maximum benefit from this 
therapy. The favorable safety profile observed with this 
interspinous spacer for treatment of LSS is attributed not 
only to careful patient selection but also because resection of 
the posterior spinal elements was not required, and therefore, 
motion of the lumbar spine is preserved.
The primary limitation of this study was the lack of 
a concurrent control group, which may have introduced 
bias into the interpretation of study outcomes. However, 
the magnitude of benefit with the interspinous spacer was 
so dramatic that nonspecific study effects such as placebo 
could not reasonably account for all of the noted clinical 
improvement.
Interspinous spacer implant with the Superion device is 
a safe and effective treatment option for carefully selected 
patients with moderate LSS who are unresponsive to 
  conservative care but are not yet eligible candidates for 
traditional spinal surgery such as laminectomy.
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